Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epigenetics double-dip

Why Atlas decided time was right to form epigenetics company Rodin

Atlas Venture's newest startup and second dip into epigenetics, Rodin Therapeutics Inc., is developing small molecule epigenetic modulators to treat Alzheimer's disease and other CNS disorders.

The VC firm has been interested in epigenetic approaches to neurologic disorders for about five years. Atlas contemplated creating a startup in 2008

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers